FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024103680> ?p ?o ?g. }

• W3024103680 abstract "Research on CAR T cells has achieved enormous progress in recent years. After the impressive results obtained in relapsed and refractory B-cell acute lymphoblastic leukemia and aggressive B-cell lymphomas, two constructs, tisagenlecleucel and axicabtagene ciloleucel, were approved by FDA. The role of CAR T cells in the treatment of B-cell disorders, however, is rapidly evolving. Ongoing clinical trials aim at comparing CAR T cells with standard treatment options and at evaluating their efficacy earlier in the disease course. The use of CAR T cells is still limited by the risk of relevant toxicities, most commonly cytokine release syndrome and neurotoxicity, whose management has nonetheless significantly improved. Some patients do not respond or relapse after treatment, either because of poor CAR T-cell expansion, lack of anti-tumor effects or after the loss of the target antigen on tumor cells. Investigators are trying to overcome these hurdles in many ways: by testing constructs which target different and/or multiple antigens or by improving CAR T-cell structure with additional functions and synergistic molecules. Alternative cell sources including allogeneic products (off-the-shelf CAR T cells), NK cells, and T cells obtained from induced pluripotent stem cells are also considered. Several trials are exploring the curative potential of CAR T cells in other malignancies, and recent data on multiple myeloma and chronic lymphocytic leukemia are encouraging. Given the likely expansion of CAR T-cell indications and their wider availability over time, more and more highly specialized clinical centers, with dedicated clinical units, will be required. Overall, the costs of these cell therapies will also play a role in the sustainability of many health care systems. This review will focus on the major clinical trials of CAR T cells in B-cell malignancies, including those leading to the first FDA approvals, and on the new settings in which these constructs are being tested. Besides, the most promising approaches to improve CAR T-cell efficacy and early data on alternative cell sources will be reviewed. Finally, we will discuss the challenges and the opportunities that are emerging with the advent of CAR T cells into clinical routine." @default.
• W3024103680 created "2020-05-21" @default.
• W3024103680 creator A5000852934 @default.
• W3024103680 creator A5004429478 @default.
• W3024103680 creator A5005399289 @default.
• W3024103680 creator A5023466579 @default.
• W3024103680 creator A5026011061 @default.
• W3024103680 creator A5029341244 @default.
• W3024103680 creator A5035469426 @default.
• W3024103680 creator A5035820057 @default.
• W3024103680 creator A5037441162 @default.
• W3024103680 creator A5042494883 @default.
• W3024103680 creator A5062571587 @default.
• W3024103680 creator A5082333371 @default.
• W3024103680 creator A5082946230 @default.
• W3024103680 creator A5088355904 @default.
• W3024103680 date "2020-05-12" @default.
• W3024103680 modified "2023-10-18" @default.
• W3024103680 title "The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice" @default.
• W3024103680 cites W1609710757 @default.
• W3024103680 cites W1619537825 @default.
• W3024103680 cites W1773485846 @default.
• W3024103680 cites W1796843950 @default.
• W3024103680 cites W1965411082 @default.
• W3024103680 cites W1965498936 @default.
• W3024103680 cites W1966542058 @default.
• W3024103680 cites W1967455230 @default.
• W3024103680 cites W1971424591 @default.
• W3024103680 cites W1976133526 @default.
• W3024103680 cites W1976400767 @default.
• W3024103680 cites W1981302308 @default.
• W3024103680 cites W1984961927 @default.
• W3024103680 cites W1987633400 @default.
• W3024103680 cites W1989566870 @default.
• W3024103680 cites W1991494425 @default.
• W3024103680 cites W1991890073 @default.
• W3024103680 cites W1993302198 @default.
• W3024103680 cites W1999088487 @default.
• W3024103680 cites W2003197307 @default.
• W3024103680 cites W2003539449 @default.
• W3024103680 cites W2005600353 @default.
• W3024103680 cites W2005837456 @default.
• W3024103680 cites W2007753570 @default.
• W3024103680 cites W2009179035 @default.
• W3024103680 cites W2009709218 @default.
• W3024103680 cites W2011445661 @default.
• W3024103680 cites W2014154395 @default.
• W3024103680 cites W2016789384 @default.
• W3024103680 cites W2020586896 @default.
• W3024103680 cites W2025074364 @default.
• W3024103680 cites W2028460943 @default.
• W3024103680 cites W2030611121 @default.
• W3024103680 cites W2033096493 @default.
• W3024103680 cites W2038702089 @default.
• W3024103680 cites W2042765435 @default.
• W3024103680 cites W2046160219 @default.
• W3024103680 cites W2046562334 @default.
• W3024103680 cites W2046596094 @default.
• W3024103680 cites W2047205338 @default.
• W3024103680 cites W2049801905 @default.
• W3024103680 cites W2056086271 @default.
• W3024103680 cites W2057389857 @default.
• W3024103680 cites W2059142229 @default.
• W3024103680 cites W2063218301 @default.
• W3024103680 cites W2064815984 @default.
• W3024103680 cites W2066540618 @default.
• W3024103680 cites W2067319054 @default.
• W3024103680 cites W2076668490 @default.
• W3024103680 cites W2082189475 @default.
• W3024103680 cites W2082708772 @default.
• W3024103680 cites W2086297371 @default.
• W3024103680 cites W2087857484 @default.
• W3024103680 cites W2088717724 @default.
• W3024103680 cites W2094945699 @default.
• W3024103680 cites W2099570622 @default.
• W3024103680 cites W2100198800 @default.
• W3024103680 cites W2105400883 @default.
• W3024103680 cites W2106606248 @default.
• W3024103680 cites W2110260408 @default.
• W3024103680 cites W2112680373 @default.
• W3024103680 cites W2118796952 @default.
• W3024103680 cites W2119896120 @default.
• W3024103680 cites W2122459559 @default.
• W3024103680 cites W2123129311 @default.
• W3024103680 cites W2125270092 @default.
• W3024103680 cites W2129702476 @default.
• W3024103680 cites W2130011407 @default.
• W3024103680 cites W2130338247 @default.
• W3024103680 cites W2134121541 @default.
• W3024103680 cites W2135215267 @default.
• W3024103680 cites W2136541422 @default.
• W3024103680 cites W2144491853 @default.
• W3024103680 cites W2145985838 @default.
• W3024103680 cites W2149858385 @default.
• W3024103680 cites W2154696313 @default.
• W3024103680 cites W2156037313 @default.
• W3024103680 cites W2161958391 @default.
• W3024103680 cites W2165984958 @default.
• W3024103680 cites W2170513194 @default.
• W3024103680 cites W2172718055 @default.

• next